Product optimisation of a novel new melanoma therapy using advanced microscopy and biomarkers to enhance the commercialisation of this technology.

黑色素瘤或皮肤癌是男性和女性中第五常见的癌症，仅在英国每天就有超过6人死亡。在过去的十年中，免疫疗法在治疗这种疾病方面显示出巨大的希望，但只有超过50%的患者对这种治疗有反应。由于每位患者的治疗费用高达数十万英镑，并且严重不良反应的数量相对较高，因此对新的替代疗法的临床需求明显未得到满足。KLAS治疗提供了一种独特的解决方案，为这种癌症提供了一种替代疗法，可以单独使用，也可以与当前的治疗方法联合使用。我们的技术通过利用一种称为光动力疗法（PDT）的过程来工作。光被用来激活我们的化合物，称为KLAS-PDT，然后将原本无害的氧气转化为杀死癌细胞的高活性形式。通过刺激人体免疫系统，KLAS-PDT可以与现有的免疫疗法相结合，从而显著降低成本并改善患者预后。该项目旨在通过生成数据包来确定光激活和剂量方案的最佳参数，从而提高这一令人兴奋的新技术的商业化。使该技术更接近于实现实际的患者利益，同时开发新的方法，可以用于分析我们最终的临床数据。

Melanoma, or skin cancer, is the 5th most common cancer in both men and women and kills more than 6 people each day in the UK alone. In the last decade, immunotherapies have shown great promise in treating this disease, but with just over 50% of patients respond to this treatment. With a price-tag running at 100's of thousands of pounds for treatment per patient and a relatively high number of serious adverse effects, there is a clear unmet clinical need for new alternative treatments.KLAS therapeutics offers a unique solution to this, by providing an alternative therapy for this cancer that can be used both independently and in combination with current treatments. Our technology works by utilising a process known as photodynamic therapy (PDT). Light is used to activate our compound, known as KLAS-PDT, which then converts otherwise harmless oxygen into a hyper reactive form that kills the cancer cells. By stimulating the body's immune system, KLAS-PDT can be combined with existing immunotherapies leading to significantly reduced cost and improved patient outcomes.This project seeks to enhance the commercialisation of this exciting new technology, by generating a data package that will confirm the optimal parameters for light activation and dosing regimen. Rendering the technology closer to achieving actual patient benefit while at the same time developing new methods that can be carried forward and translated for the analysis of our eventual clinical data.